独特的不尤
Lv11
26 积分
2022-08-22 加入
-
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
1小时前
已完结
-
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
3小时前
已完结
-
Comparison between AWGC-cachexia and GLIM-malnutrition in patients with gastric cancer
3个月前
已完结
-
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
3个月前
已完结
-
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
4个月前
已完结
-
A deep learning model with incorporation of microvascular invasion area as a factor in predicting prognosis of hepatocellular carcinoma after R0 hepatectomy
4个月前
已完结
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
6个月前
已完结
-
Cholangiocarcinoma imaging: from diagnosis to response assessment
6个月前
已完结
-
Combining systemic and local therapies for hepatocellular carcinoma
8个月前
已完结
-
Cancer incidence and mortality in China, 2022
8个月前
已完结